Rankings
▼
Calendar
AQST Q3 2025 Earnings — Aquestive Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
AQST
Aquestive Therapeutics, Inc.
$431M
Q3 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$13M
-5.4% YoY
Gross Profit
$8M
64.8% margin
Operating Income
-$11M
-89.6% margin
Net Income
-$15M
-120.6% margin
EPS (Diluted)
$-0.14
QoQ Revenue Growth
+28.0%
Cash Flow
Operating Cash Flow
-$13M
Free Cash Flow
-$13M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$164M
Total Liabilities
$168M
Stockholders' Equity
-$4M
Cash & Equivalents
$129M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$13M
$14M
-5.4%
Gross Profit
$8M
$9M
-8.8%
Operating Income
-$11M
-$8M
-38.5%
Net Income
-$15M
-$12M
-34.2%
Revenue Segments
Manufacture and Supply Revenue
$11M
90%
License and Royalty Revenue
$1M
8%
Co-Development and Research Fees
$302,000
2%
Geographic Segments
UNITED STATES
$10M
79%
Non-US
$3M
21%
← FY 2025
All Quarters
Q4 2025 →